Wang F S, Kobayashi H, Liang K W, Holland J F, Ohnuma T
Samuel Bronfman Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Hum Gene Ther. 1999 May 1;10(7):1185-95. doi: 10.1089/10430349950018175.
Development of multidrug resistance (MDR) is the major obstacle to successful cancer chemotherapy. We have developed Daudi human lymphoma cells that are 20-fold more resistant than the parent cell line to vincristine (VCR) by infecting cells with pHaMDR1/A retroviral vector (Daudi/MDR20). Three DNA sequences of anti-MDR1 hammerhead ribozymes (Rzs), one cleaving codon 196 of MDR1 mRNA (196MDR1-Rz), the second a stem II base-modified (U9-->Gg, U13-->A13, G14-->A14, A18-->C18) Rz against codon 196 (196MDR1-sRz), and the third a stem II base-modified Rz directed against the -6 approximately -4 GUC sequence of the translation initiation site of the MDR1 mRNA (iMDR1-sRz), were synthesized and cloned into the retroviral vector N2A+tRNAiMet downstream of the RNA polymerase III promoter and adjacent to a tRNA gene sequence, forming the constructs N2A+tRNAiMet-196MDR1-Rz, N2A+tRNAiMet-196MDR1-sRz, and N2A+tRNAiMet-iMDR1-sRz. The three constructs were transfected into GP+envAM 12 cells for packaging the retroviral vectors. The supernatants containing the packaged retrovirus in high titers (1.1-2.5 X 10(5) CFU/ml as determined by infection of NIH 3T3 cells) were used to infect Daudi/MDR20 cells. The iMDR1-sRz- and 196MDR1-sRz-transduced Daudi/MDR20 cells completely restored chemosensitivity to VCR and doxorubicin, and were accompanied by blocked expression of MDR1 mRNA and P-glycoprotein as well as overexpression of anti-MDR1 Rz. In a cell-free system, the chimeric tRNA-sRz molecules were more stable and had more efficient catalytic activities than the corresponding naked Rz molecules. The stem II base-modified Rz were also more stable and efficient in catalytic activities than the unmodified Rz molecules. The base modification in the Rz stem II structure and the development of chimeric tRNA-Rz molecules were identified to enhance the cleavage efficacy. The combination of these two factors, together with the use of a retroviral vector, appear to have contributed to the complete reversal of MDR.
多药耐药性(MDR)的产生是癌症化疗成功的主要障碍。我们通过用pHaMDR1/A逆转录病毒载体感染细胞,构建了对长春新碱(VCR)的耐药性比亲代细胞系高20倍的Daudi人淋巴瘤细胞(Daudi/MDR20)。合成了三种抗MDR1锤头状核酶(Rz)的DNA序列,一种切割MDR1 mRNA密码子196(196MDR1-Rz),第二种是针对密码子196的茎II碱基修饰(U9→Gg、U13→A13、G14→A14、A18→C18)的Rz(196MDR1-sRz),第三种是针对MDR1 mRNA翻译起始位点-6至-4 GUC序列的茎II碱基修饰的Rz(iMDR1-sRz),并将它们克隆到逆转录病毒载体N2A+tRNAiMet中,位于RNA聚合酶III启动子下游且与tRNA基因序列相邻,形成构建体N2A+tRNAiMet-196MDR1-Rz、N2A+tRNAiMet-196MDR1-sRz和N2A+tRNAiMet-iMDR1-sRz。将这三种构建体转染到GP+envAM 12细胞中以包装逆转录病毒载体。含有高滴度包装逆转录病毒的上清液(通过感染NIH 3T3细胞测定为1.1 - 2.5×10⁵ CFU/ml)用于感染Daudi/MDR20细胞。转导了iMDR1-sRz和196MDR1-sRz的Daudi/MDR20细胞完全恢复了对VCR和阿霉素的化学敏感性,同时伴随着MDR1 mRNA和P-糖蛋白表达的阻断以及抗MDR1 Rz的过表达。在无细胞系统中,嵌合tRNA-sRz分子比相应的裸露Rz分子更稳定且具有更高效的催化活性。茎II碱基修饰的Rz在催化活性方面也比未修饰的Rz分子更稳定且高效。已确定Rz茎II结构中的碱基修饰和嵌合tRNA-Rz分子的开发可提高切割效率。这两个因素与逆转录病毒载体一起使用似乎有助于MDR的完全逆转。